Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma

Radiother Oncol. 2009 Jul;92(1):96-9. doi: 10.1016/j.radonc.2009.03.011. Epub 2009 Apr 11.


Background and purpose: The combination of chemotherapy, surgery, and radiotherapy has improved the prognosis for patients with malignant pleural mesothelioma (MPM). Intensity-modulated radiotherapy (IMRT) has allowed for an increase in dose to the pleural cavity and a reduction in radiation doses to organs at risk. The present study reports and analyses the incidence of fatal pulmonary toxicity in patients treated at Rigshospitalet, Copenhagen.

Materials and methods: Twenty-six patients were treated with induction chemotherapy followed by extrapleural pneumonectomy and IMRT between April 2003 and April 2006. The entire preoperative pleural surface area was treated to 50 Gy and areas with residual disease or close surgical margins were treated to 60 Gy in 30 fractions.

Results: The main toxicities were nausea, vomiting, esophagitis, dyspnea, and thrombocytopenia. One patient died from an intracranial hemorrhage during severe thrombocytopenia. Four patients (15%) experienced grade 5 lung toxicity, i.e. pneumonitis 19-40 days after the completion of radiotherapy. Patients with pneumonitis had a significantly larger lung volume fraction receiving 10 Gy or more (V10) (median: 60.3%, range 56.4-83.2%) compared to patients without pneumonitis (median: 52.6%, range: 25.6-80.3%) (p=0.02). Mean lung dose (MLD) was also significantly higher in patients who developed pneumonitis (median 13.9 Gy, range: 13.6-14.2 Gy) than in patients who did not (median=12.4 Gy, range: 8.4-15.4 Gy) (p=0.04).

Conclusions: Significant differences in MLD and V10 for patients with fatal pulmonary toxicity compared to patients without fatal lung toxicity have been demonstrated. Based on the presented data local lung dose constraints have been modified in order to avoid unacceptable toxicity.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Combined Modality Therapy
  • Female
  • Humans
  • Male
  • Mesothelioma / drug therapy
  • Mesothelioma / radiotherapy*
  • Mesothelioma / surgery
  • Middle Aged
  • Pleural Neoplasms / drug therapy
  • Pleural Neoplasms / radiotherapy*
  • Pleural Neoplasms / surgery
  • Pneumonectomy
  • Radiation Dosage
  • Radiation Pneumonitis*
  • Radiotherapy, Intensity-Modulated / adverse effects*
  • Treatment Outcome